Vir (VIR), Glaxo’s Xevudy Wins EC Approval for COVID-19

Vir Biotechnology, Inc. (VIR) and partner GlaxoSmithKline obtain the European Commission’s nod for Xevudy for the early treatment of COVID-19.

Leave a Reply

Your email address will not be published. Required fields are marked *